<DOC>
	<DOCNO>NCT00003171</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness bryostatin 1 treat patient myelodysplastic syndrome .</brief_summary>
	<brief_title>Bryostatin 1 Treating Patients With Myelodysplastic Syndrome</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate bryostatin 1 patient myelodysplastic syndrome . II . Determine qualitative quantitative toxic effect bryostatin 1 . III . Determine duration response survival patient receive therapy . OUTLINE : This two stage study . Patients receive bryostatin 1 continuous infusion 72 hour every 14 day 4 cycle . Responding patient may continue treatment absence disease progression unacceptable toxicity . Patients complete response receive 2 additional cycle . Patients response receive 4 additional cycle . Patients re-evaluated every 4 cycle . PROJECTED ACCRUAL : 14 27 patient accrue within 2 year 2 stage study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Bryostatin 1</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically diagnose refractory anemia , refractory anemia excess blast , refractory anemia excess blast transformation , refractory anemia ring sideroblast , chronic myelomonocytic leukemia significant cytopenia least 4 week duration No 1 prior treatment disease Not eligible allogeneic bone marrow transplantation le 60 year age PATIENT CHARACTERISTICS : Age : 18 Performance status : Zubrod 02 Life expectancy : At least 12 week Hematopoietic : Hematocrit le 26 % ( require transfusion ) least 4 week Absolute neutrophil count le 1000/mm3 least 4 week Platelet count le 50/mm3 least 4 week Hepatic : Bilirubin le 1.5 mg/dL Transaminase le 2.5 time upper limit normal Renal : Creatinine le 1.5 mg/dL Creatinine clearance least 60 mL/min Other : Not pregnant lactate Fertile patient must use effective contraception study 100 day afterwards No uncontrolled lifethreatening infection PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy No concurrent treatment growth factor Chemotherapy : At least 4 week since prior chemotherapy ( 8 week mitomycin nitrosourea ) recover Endocrine therapy : No concurrent use steroid Radiotherapy : At least 4 week since prior radiation therapy recover Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>refractory anemia</keyword>
	<keyword>refractory anemia ring sideroblast</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
</DOC>